Q1 2026 Boston Scientific Corp Earnings Call Transcript
Key Points
- Boston Scientific Corp (BSX) reported a solid first quarter with organic sales growth of 9.4%, aligning with their guidance range.
- The company achieved the high end of their adjusted EPS guidance range with $0.80, reflecting a 6% growth.
- Strong performance in the Asia Pacific region, with 12% operational growth, driven by double-digit growth in Japan and China.
- The Neuromodulation segment experienced a robust quarter with 15% organic sales growth.
- The Interventional Oncology business grew 15% organically, supported by new FDA clearances and product launches.
- Boston Scientific Corp (BSX) reduced its full-year guidance due to unanticipated headwinds, now expecting 6.5% to 8% organic growth.
- The Urology segment underperformed with only 1% organic growth, impacted by challenges in stone management and neuromodulation.
- Cardiac Rhythm Management sales declined by 3% in the quarter, facing tough comparisons and regional challenges.
- The WATCHMAN segment's growth was below expectations, with pressures on volumes in the US due to hospital capacity and reimbursement dynamics.
- The company anticipates lower-than-expected product mix benefits and incremental investments impacting gross margins for the full year 2026.
Good morning, and welcome to the Boston Scientific first quarter 2026 earnings call. (Operator Instructions) Please note, this event is being recorded.
I would now like to turn the conference over to Lauren Tengler, Vice President, Investor Relations. Please go ahead.
Thank you, Bailey, and thanks to everyone for joining us. With me today are Mike Mahoney, Chairman and Chief Executive Officer; Jon Monson, Executive Vice President and Chief Financial Officer. During the Q&A session, Mike and John will be joined by our Chief Medical Officer, Dr. Ken Stein.
We issued a press release earlier this morning announcing our Q1 2026 results, which included reconciliations of the non-GAAP measures used in this release. The release as well as reconciliations of non-GAAP measures used in today's call can be found on the Investor Relations section of the website.
Please note that on the call, operational revenue excludes the impact of foreign currency fluctuations,
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
